# OnCo record sclc-molecular-subtypes (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/sclc-molecular-subtypes/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "sclc-molecular-subtypes" ;
  schema:name "Small-cell lung cancer transcription-factor subtypes (SCLC-A, SCLC-N, SCLC-P, SCLC-I) and SLFN11"@en ;
  schema:alternateName "SCLC-A"@en, "SCLC-N"@en, "SCLC-P"@en, "SCLC-I"@en, "ASCL1"@en, "NEUROD1"@en, "POU2F3"@en, "YAP1 subtype"@en, "inflamed SCLC"@en, "SCLC subtypes"@en, "small cell lung cancer molecular subtypes"@en, "SLFN11"@en, "SLFN11 expression"@en, "neuroendocrine-high"@en, "neuroendocrine-low"@en, "transcription factor subtype"@en ;
  schema:description "Small-cell lung cancer has looked like one disease for fifty years; RNA profiling now splits it by the master transcription factor in charge (ASCL1, NEUROD1, POU2F3, or none with an inflamed signature), and these groups, plus the DNA-damage protein SLFN11, are the first leads for matching drugs to a cancer that has had almost no biomarkers."@en ;
  schema:url <https://onco.cc/terms/sclc-molecular-subtypes/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  onco:related <https://onco.cc/targets/dll3/>, <https://onco.cc/drugs/tarlatamab/>, <https://onco.cc/drugs/ifinatamab-deruxtecan/>, <https://onco.cc/drugs/lurbinectedin/>, <https://onco.cc/technologies/rna-seq/>, <https://onco.cc/terms/ihc/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/targets/parp/> ;
  onco:cancers <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/limited-stage-sclc/>, <https://onco.cc/cancers/extensive-stage-sclc/> .